According to this pivotal role in cell growth, mutations in EGFR gene, such as the copy number alteration, are frequently recurrent in cancer, thereby leading to EGFR overexpression and constitutive activation at the surface of tumor cells: for example, HER2 overexpression occurs in 15-30% of breast cancers and in 43-89% of the non-small cell lung carcinomas [55, 56]. This evidence concerns the gene EGFR and breast carcinoma.